reason report
pharma medic improv though invest need
bottom line follow earn call morn
increment posit stock brand gener price
trend appear stabil believ gener buy-sid
rate come slightli better expect pharma beat
oper incom estim divis oper profit would
flat y/i except invest medic oper profit
would grown y/i inventori charg
view indic core busi perform well
seem turn corner adj ep guidanc rais
reflect benefit new lower tax rate medic
segment expect grow revenu high-teen despit
headwind exam glove slower-than-expect ramp cordi
pharma revenu expect continu grow low-to mid-
singl digit rais estim reflect revis guidanc
effect tax reform pt stand though increas
estim reflect lower tax rate improv core earn
guid updat reflect tax reform manag rais
adj ep guidanc due primarili benefit tax reform
expect adj ep rang
also expect revenu growth mid-singl
digit low-to mid-singl digit revenu growth pharma segment
high-teen growth medic segment pharma segment profit
expect low-doubl digit y/i result sale china
busi invest relat custom initi opioid
medic segment profit expect post double-digit revenu growth
despit headwind cordi exam glove estim
guidanc provid august view quarter
good show progress core busi add back
inventori charg would near oper margin
medic believ still expect signific accret
patient recoveri busi despit
headwind glove cordi medic busi seem
perform well within pharma believ gener brand price
stabil guid doubl digit y/i declin oper
incom pharma howev exclud pharma
invest spend oper incom would flat quarter
invest requir futur addit initi
primari concern drug price seem stabl
net debt total capit
ep
compani inform leerink partner llc research
revenu present billion dollar
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
pharmaceut divis perform well price stabil
pharma segment post good perform quarter
led part specialti nuclear busi oper profit
segment impact on-going invest pharma
platform system depreci manag cite januari
price increas bring brand inflat in-lin expect
gener price also appear track in-lin guidanc
manag explain redoak perform well
deliv result cost side slightli ahead expect
believ driver beat rel
model pharma oper margin increas bp q/q exceed
estim bp price commentari consist
commentari peer industri data
medic divis face headwind cordi medic glove
expect post good double-digit growth medic
segment post decent result quarter help patient
recoveri busi includ full quarter estim
without contribut patient recoveri busi
profit segment would flat slightli appear
cordi medic glove provid headwind may
persist near-term believ cordi ramp quickli
expect earn growth asset take time
medic glove also headwind expect persist
near-term medic glove signific high volum compon
medic divis contract typic fix price
result fluctuat commod cost materi impact
compound headwind suppli issu manufactur work
compli environment regul abroad shift suppli
new locat better meet demand product shortfal
commod price headwind expect continu despit
headwind manag expect divis continu growth
guid high-teen revenu double-digit segment profit
growth
tweak estim pt remain adjust model
quarter updat guidanc revenu estim increas
slightli account quarter tweak ep reflect
better tax rate increas revenu slightli reflect
better growth pharma divis increas adj ep
estim primarili due lower tax rate benefit rel
previou model pt stand new
adj ep estim
gener cautiou pharmaceut distribut busi given greater scrutini
around drug price deceler brand gener inflat trend slow-down gener
launch calendar lack transpar industri revenu earn model
headwind partial off-set industri high cash flow characterist abil leverag
larg fix cost infrastructur on-going wave specialti bio-similar small-molecul
gener launch util level remain somewhat depress believ cardin
done good job execut tuck-in acquisit grow footprint faster grow
market segment includ home health medic surgic distribut pharmaceut
distribut china compani presenc china also help sourc
higher margin prefer product add cardin product portfolio
believ manag highli compet believ new purchas jv op
extend distribut contract creat opportun expans cardin
distribut relationship time manag team
high qualiti cash-flow characterist good mani near medium
term headwind view includ slow-down brand gener inflat slow
gener launch calendar potenti volum headwind tie unwind given
headwind rate share market perform
stock trade ep estim
histor ntm price-to-earnings averag next month expect share trade
ep would put stock use slightli lower
multipl valuat analysi due delay recogn accret cordi risk
patient recoveri integr continu margin pressur pharmaceut divis
despit price stabil still face challeng price environ difficult
sell-sid margin despit better perform medic maintain mp rate due
headwind includ brand gener price competit downstream sell-
side environ potenti weaken volum due unravel piec
hepat comp signific slowdown valu brand convert
gener next year
competit intens custom concentr high compet
op mp well sever smaller medical-
surgic distributor includ owen minor mp inc mp
result competit custom buy-sid sell-sid may constantli tri
pressur margin novat premier larg custom present renew risk
lose custom custom put signific margin
pressur compani earn could come pressur
price could declin reform also pose risk price brand-
name drug gener declin time margin could come
pressur addit patient protect afford act health
educ reconcili act implement signific chang industri exampl
increas rebat paid manufactur fee must paid could
advers impact buy-sid margin abl earn addit retail
pharmaci face margin pressur due chang medicaid reimburs chang
awp could pressur compani sell-sid margin
regul extens drug distribut busi subject extens law
regul cover mani aspect compani oper includ fraud abus
law prescript drug pedigre track mani requir mandat
fda state feder law agenc compani requir hold
licens permit oper distribut center
tax posit pose risk oper mani state throughout
world tax law complex within intern perspect
addit ever refin lifo account could advers impact
inform system compani reli inform system within corpor
offic throughout distribut center technolog system complex
requir facilit purchas distribut thousand inventori line-item receiv
process ship order manag bill collect process payment mani
function reason technolog system fail function properli
earn could face substanti risk
acquisit integr could risk perform fair number
acquisit past sever year may continu acquir futur
compani fail integr acquisit onto platform
inform technolog personnel structur issu integr process
compani earn could risk
concentr supplier pose risk supplier make
revenu five supplier gener compani busi contract
typic written one-year basi automat renew year five year given
somewhat high degre concentr among manufactur
depend honor supplier agreement relationship
end deterior manufactur put price pressur
compani earn could risk addit depend raw
materi commod includ nuclear materi price oil impact distribut
econom trend compani global oper impact econom trend
exampl recess could caus patient less will go physician
offic certain procedur done out-of-pocket cost could view substanti
peopl unemploy worri becom unemploy howev
econom trend overal employ improv medical-surg distribut busi
could improv significantli transact exposur hedg
incom statement model fiscal year end june
million
good sold
total revenu
total revenu
sale carefus stock
loss debt extinguish
weight average number share
incom statement model fiscal year end june
million
margin expans bp
margin expans bp
